



60 years ofCimicifuga racemosamedicinal products
Clinical researchmilestones, current study findings and current development
Hans-Heinrich Henneicke-von Zepelin
Received: 7 October 2016 / Accepted: 15 December 2016
© The Author(s) 2017. This article is available at SpringerLink with Open Access.
Summary Cimicifuga racemosa (CR) extracts are im-
portant worldwide as therapy for menopausal symp-
toms. The first medicinal product from CR has been
available since 1956 (Germany, Remifemin® [Schaper
& Brümmer, Salzgitter, Germany], isopropanolic ex-
tract iCR). This review describes how CR developed,
via clinical studies on safety (breast, breast cancer, en-
dometrium, liver) and efficacy, into a successful and
safe medicinal product in Germany, Europe and the
world. In line with developing legal frameworks for
medicinal products in Germany and Europe, clinical
studies on CR were observational during the 50s and
70s, and controlled studies since the 80s. The first
placebo-controlled study emerged 1986. From 2000
to 2015, a total of 28 clinical studies in Europe, Ame-
rica and Asia were published on the efficacy of CR.
In these studies, 11,073 patients received a CR-based
medicinal product, 93% thereof iCR. A meta-analysis
of all nine placebo-controlled studies published un-
til 2013 confirmed the reliable efficacy of CR-based
medicinal products for menopausal symptoms.
Keywords Climacteric complaints · Cimicifuga race-
mosa · Actaea racemosa · Black Cohosh · Survival after
breast cancer · Osteoporosis · Myoma · Cognition
60 Jahre Arzneimittel aus Cimicifuga racemosa
Meilensteine klinischer Forschung, aktuelle
Studienergebnisse und derzeitige Entwicklung
Zusammenfassung Extrakte aus Cimicifuga racemosa
(CR) haben zur Therapie von Wechseljahresbeschwer-
Dr. H.-H. Henneicke-von Zepelin ()
Clinical Research, Schaper & Brümmer GmbH & Co. KG,
Bahnhofstraße 35, 38259 Salzgitter, Germany
h.v.zepelin@schaper-bruemmer.de
den weltweit an Bedeutung gewonnen. Das erste
aus CR hergestellte Fertigarzneimittel steht seit 1956
zur Verfügung (Deutschland, Remifemin® [Schaper
& Brümmer, Salzgitter, Deutschland], isopropanoli-
scher Extrakt aus CR, iCR). Diese Übersichtsarbeit
beschreibt, wie sich CR durch klinische Studien zur
Sicherheit (Brust, Brustkrebs, Endometrium, Leber)
und Wirksamkeit zu einem erfolgreichen und siche-
ren Arzneimittel in Deutschland, Europa und weltweit
entwickelt hat. In Übereinstimmung mit der jeweili-
gen Entwicklung der gesetzlichen Rahmenbedingun-
gen zu Arzneimitteln wurden klinische Studien zu
CR in den 1950er- und 1970er- Jahren als beobach-
tende Studien durchgeführt. Seit den 1980er-Jahren
folgten kontrollierte Studien, darunter die erste place-
bokontrollierte Studie 1986. Von 2000 bis 2015 wurden
insgesamt 28 klinische Studien aus Europa, Amerika
und Asien zur Wirksamkeit von CR veröffentlicht. In
diesen Studien erhielten 11.073 Patientinnen ein CR-
Arzneimittel, 93% davon iCR. Eine Metaanalyse aller
9 bis 2013 veröffentlichten placebokontrollierten Stu-
dien bestätigte die zuverlässige Wirksamkeit von CR-
Arzneimitteln gegen Wechseljahresbeschwerden.
Schlüsselwörter Wechseljahresbeschwerden · Cimi-
cifuga racemosa · Actaea racemosa · Traubensil-
berkerze · Überleben nach Brustkrebs · Osteoporose ·
Myom · Kognition
Short Overview
Approximately four out of five women suffer from
menopausal symptoms (MPS) such as hot flushes
and sweating, as well as from sleep disorders as-
sociated with these symptoms. Many women also
suffer from psychological symptoms such as mood
disorders, nervousness and irritability. For decades,
extracts made from the rhizome of Cimicifuga race-
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mosa (L.) Nutt. (CR, synonym for Actaea racemosa L.,
‘Traubensilberkerze’, black cohosh) have been gaining
worldwide importance as therapy for MPS. This herbal
substance was originally used in North American folk
medicine. The first medicinal product produced from
black cohosh has been available since 1956 (Ger-
many, Remifemin® [Schaper & Brümmer, Salzgitter,
Germany], isopropanolic extract iCR). At about the
same time, Kupperman established his Menopause
Index (KMI), which has since been used in numerous
clinical studies with CR. From the 50s to the 70s, clin-
ical research on CR followed the common practice
of documenting and publishing clinical experiences.
The German Medicines Act from 1976 enacted the
obligation to provide proof of efficacy. Appropriately,
controlled clinical trials followed in the 80s. From
1985 to 1987, the German Ministry of Health estab-
lished standards on how to conduct clinical trials for
drugs, i. e. medicinal products. Accordingly, the first
randomized, placebo-controlled clinical trial with any
CR extract was conducted (1986, iCR, KMI, Germany).
Good Clinical Practice (GCP) first came into ef-
fect in 1991 and was harmonized by the International
Conference of Harmonization (ICH) in 1996. In 1994,
Hauser published his Menopause Rating Scale (MRS)
as a new tool to measure menopausal symptoms. A
factor analysis established four MRS-I subscores in
2000; a self-assessment version appeared as MRS-II
and is meanwhile available in 27 languages.
The first GCP compliant clinical study with CR in
1995 was dedicated to the question of dose–efficacy
relationship (KMI, Poland). Daily doses of iCR ex-
tract from up to 127mg CR proved to be safe. With-
out differentiating according to menopausal status,
40mg already showed sufficient efficacy. However,
perimenopausal women profited more from 127mg
than from 40mg.
The second placebo-controlled clinical study for
iCR followed from 2002 to 2005 (MRS, Germany). In
addition to proof of efficacy, factors that influence effi-
cacy were revealed and the first subtle hints of a supra-
hypothalamic CNS (central nervous system) influence
were found.
In 2003, the first placebo-controlled study with a
Cimicifuga product from an ethanolic extract
(Klimadynon® [Bionorica, Neumarkt, Germany]) was
published. The study strengthens the MRS by estab-
lishing the MRS-based effect size of hormone therapy
(HT) for MPS compared to placebo (Czech Republic).
Controlled studies comparing iCR with other MPS
therapies showed no differences in efficacy compared
to hormone patches (2005, Italy) and tibolone, but iCR
was superior regarding safety (2007, China). Another
CR product (Remixin® [Mikro-Gen, Istanbul, Turkey])
was compared to fluoxetine, with inferiority in the
psychological component of the MPS and superiority
in the KMI (2008, Turkey).
In 2005/2008, a clinical study clinically proved a
CNS influence of iCR using positron emission tomog-
raphy (USA). This is consistent with the pathophysio-
logical tests in which CNS cortical activation accom-
panied menopausal hot flushes (2006, USA).
To date, the largest clinical study with CR (n = 6141,
Germany) was published 2005/2007 and, for the first
time, included over 12 months of safety data on pa-
tients (n = 736). iCR was compared with a combined
product containing iCR and St. John’s wort (HP). iCR-
HP showed an additional benefit on the psychological
component of MPS. Proof of efficacy for this combi-
nation was also obtained using a placebo-controlled
study (2006, MRS, Germany).
In 2006, a clinical study on safety at the en-
dometrium with a 12-month CR therapy followed
(Poland, Czech Republic).
The safety of iCR on breast tissue (mammography
and fine-needle aspiration biopsy) was also substan-
tiated with a clinical study: in 2007 alone, and in 2011
in a meta-analysis comparison with placebo, HT and
tibolone (Sweden). Additionally, a pharmacoepidemi-
ological cohort study demonstrated a 4.5-year longer
recurrence-free survival after breast cancer for iCR
users (2007, Germany).
In 2010, the Herbal Medicinal Product Committee
(HMPC) of the European Medicinal Agency mono-
graph attested the well-established use of drugs con-
taining CR extract based on previously published
studies on menopausal symptoms. According to the
HMPC, there is no limit on the length of use, but after
6 months of therapy, a medical professional should
be consulted. Breast cancer patients are not excluded
from treatment of MPS with CR as long as a medical
professional is consulted.
In 2011 the first meta-analysis was dedicated to the
topic of liver safety. Of all five controlled clinical stud-
ies with iCR available at the time, the liver function
test values were summarized where they had been
raised. Evidence of liver toxicity was not found (in-
ternational).
From 2000 to 2015, a total of 28 clinical studies in
Europe, America and Asia were published on the effi-
cacy of CR. In these studies, 11,073 patients received
a CR drug, 93% thereof iCR. In 2013 a corrective re-
ply to a Cochrane report on CR presented a complete
meta-analysis of all nine placebo-controlled studies
published until then; the report confirmed the reli-
able efficacy of CR drugs (international).
A recent study analysis evidenced that in women
who were treated with iCR for MPS, myomas shrank in
size compared to therapy with tibolone (2014, China).
The latest placebo-controlled clinical study with iCR
came from China. It showed improvement in sleep
quality.
Future CR researchmay be dedicated to such topics
as: mechanisms of action, possible extension of indi-
cations (e. g. prophylaxis for breast cancer recurrence)
or additional uses (e. g. improvement of osteoporosis
fractures or cognitive abilities). To date, the results
of clinical research with CR confirm its safety and
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efficacy for menopausal symptoms and also provide
valuable insights into additional uses, mechanisms of
action and more.
Kurzübersicht
Etwa 4 von 5 Frauen leiden während ihrer Wech-
seljahre an Beschwerden (WJB) wie Hitzewallun-
gen, Schweißausbrüchen und damit assoziierten
Schlafstörungen, etliche zusätzlich an psychischen
Symptomen wie Verstimmungszuständen, Nervosität
und Reizbarkeit. Seit Jahrzehnten gewinnt deren
Therapie mit Extrakten aus dem Wurzelstock von
Cimicifuga racemosa (L.) Nutt. (CR, synonym für
Actaea racemosa L., Traubensilberkerze, Black Co-
hosh) weltweit an Bedeutung. Diese Arzneidroge
stammt ursprünglich aus der Volksmedizin Nord-
amerikas. Das erste hieraus hergestellte Fer-
tigarzneimittel steht seit 1956 zur Verfügung (Deutsch-
land, Remifemin® [Schaper & Brümmer, Salzgit-
ter, Deutschland], isopropanolischer Extrakt, iCR).
Etwa zeitgleich etablierte Kupperman seinen Meno-
pause-Index (KMI, 1953–1959), der seither in di-
versen klinischen Studien zu CR eingesetzt wurde.
In den 1950er- bis 1970er- Jahren folgte die klinische
Forschung zu CR dem damals üblichen Vorgehen,
dem Dokumentieren und Veröffentlichen von klini-
schen Erfahrungswerten. Das Arzneimittelgesetz 1976
führte die Pflicht zum Nachweis der Wirksamkeit ein,
entsprechende kontrollierte klinische Studien folg-
ten in den 1980er- Jahren. Das BMJFFG (Bundes-
ministerium für Jugend, Familie, Frauen und Gesund-
heit) erließ 1985–1987 Grundsätze für die Durch-
führung der klinischen Prüfung von Arzneimitteln.
Entsprechend wurde die erste randomiserte place-
bokontrollierte klinische Prüfung zu CR durchgeführt
(1986, iCR, KMI, Deutschland).
Good Clinical Practice (GCP) trat erstmals 1991
und dann 1996 ICH-harmonisiert, also gemäß Inter-
national Conference(s) of Harmonization, in Kraft.
Hauser veröffentlichte 1994 seine Menopause Rating
Scale MRS als neues Messinstrument von Wechsel-
jahresbeschwerden, für die 2000 eine Faktorenana-
lyse die MRS-I-Subskalen etablierte und eine Selbst-
beurteilungsvariante als MRS-II erschien, in mittler-
weile 27 Sprachen verfügbar.
Die erste GCP-konforme klinische Studie zu CR
widmete sich 1995 der Fragestellung zur Dosis-Wirk-
samkeits-Beziehung (KMI, Polen). Tagesdosen an
iCR-Extrakt aus bis zu 127 mg CR erwiesen sich als
sicher. Ohne Differenzierung nach Menopausesta-
tus waren bereits 40 mg ausreichend wirksam. Doch
perimenopausale Frauen profitierten von 127 mg
mehr als von 40 mg.
In den Jahren 2002–2005 folgte die zweite place-
bokontrollierte klinische Prüfung zu iCR (MRS,
Deutschland). Neben dem Wirksamkeitsbeleg ar-
beitete sie Einflussgrößen auf die Wirksamkeit heraus
und ergab erste Hinweise auf einen suprahypothala-
mischen ZNS-Einfluss von iCR.
Die erste placebokontrollierte Studie zu einem
Cimicifuga-Produkt mit einem ethanolischen Extrakt
wurde 2003 publiziert (Klimadynon® [Bionorica, Neu-
markt, Deutschland]). Sie etablierte die MRS-basierte
Effektgröße einer Hormontherapie der WJB im Ver-
gleich zu Placebo und CR (Tschechien).
Kontrollierte Studien zumVergleich von iCRmit an-
deren WJB-Therapien ergaben keinen Wirksamkeits-
unterschied zu Hormonpflastern (2005, Italien) und
zu Tibolon bei gleichzeitiger Überlegenheit in puncto
Sicherheit (2007, erstmals China). Ein weiteres CR-
Produkt (Remixin® [Mikro-Gen, Istanbul, Türkei])
steuerte 2008 eine kontrollierte Studie im Vergleich zu
Fluoxetin bei, mit Unterlegenheit in der psychischen
Komponente der WJB und Überlegenheit im KMI
(Türkei).
Eine klinische Studie belegte 2005/2008 den den
ZNS-Einfluss von iCR klinisch per Positronenemis-
sionstomographie (USA). Dies ist vereinbar mit patho-
physiologischen Untersuchungen, in denen meno-
pausale Hitzewallungen mit ZNS-kortikaler Aktivie-
rung einhergingen (2006, USA).
Die bisher größte klinische Studie zu CR (n = 6141)
stammt aus 2005 (Deutschland), davon 736 Patientin-
nen mit Sicherheitsdaten erstmals über 12 Monate.
Sie verglich iCR mit einem Kombinationsprodukt aus
iCR und Johanniskraut (HP) und zeigte für iCR-HP
einen zusätzlichen Benefit-Effekt auf die psychische
Komponente der WJB. Auch für diese Kombination er-
folgte der Wirksamkeitsbeleg mittels placebokontrol-
lierter Studie (2006, MRS, Deutschland).
Im Jahr 2006 folgte eine klinische Studie zur Sicher-
heit am Endometrium unter 12-monatiger CR-Thera-
pie (Polen, Tschechien).
Die iCR-Sicherheit am Brustgewebe (Mammogra-
phie und Feinnadelbiopsie) wurde auch mittels kli-
nischer Studie untermauert: 2007 allein und 2011
in metaanalytischem Vergleich zu Placebo und Ti-
bolon (Schweden). Zudem ergab eine pharmakoepi-
demiologische Kohortenstudie ein 4,5 Jahre längeres
rezidivfreies Überleben für iCR-Anwenderinnen nach
Brustkrebs (2007, Deutschland).
2010 attestierte das HMPC (Herbal Medicinal Prod-
uct Committee der European Medicinal Agency) per
Monographie einen Well Established Use von CR-
Extrakt-haltigen Arzneimitteln auf Basis der bis dahin
publizierten Studien bei WJB. Gemäß HMPC beinhal-
tet die Anwendungsdauer keine zeitliche Begrenzung,
nach 6 Monaten Therapiedauer soll jedoch ärztlicher
Rat eingeholt werden. Die Behandlung mit CR von
WJB schließt auch Brustkrebspatientinnen nicht aus,
sofern ein entsprechender Rat vom Arzt eingeholt
wird.
Die erste Metaanalyse widmete sich 2011 dem
Thema Lebersicherheit. Sie fasste die Leberfunktions-
werte aller 5 bis dahin verfügbaren kontrollierten
klinischen Studien zu iCR zusammen, in denen diese
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Table 1 Curriculumvitae. Milestonesof clinical research in thecareer of the first industrial herbalmedicinal product containing
anextract ofCimicifuga racemosa (CR)
Year Milestone Country/region
1956 Year of birth of Remifemin® Germany
1956 to 1970s Documentation of clinical experiences Germany
1980s First randomized controlled clinical trials according to 1976 Medicines Act Germany
1986 First placebo-controlled clinical trial on iCR Germany
1989 German Commission E monograph on CR Germany
1991 Good Clinical Practice Europe
1995 First clinical dose–efficacy study Poland
2003 First placebo-controlled study on another CR extract; MRS-based effect size of hormone therapy (HT) Czech Republic
2002 to 2005 Second placebo-controlled study on iCR confirms efficacy, identifies confounders influencing the effect size, first
subtle hints of supra-hypothalamic CNS influence
Germany
2005 Controlled study in comparison to hormone patches Italy
2005/2008 Clinical evidence on CNS influence of iCR by PET USA
2007 Controlled study in comparison to tibolone, first study in China China
2007 Clinical study on iCR safety in breast tissue Sweden
2007 Pharmacoepidemiological cohort study on recurrence-free survival after breast cancer Germany
2010 Monograph of the Herbal Medicinal Product Committee at the European Medicines Agency concludes well-estab-
lished use of CR-based medicines for alleviating menopausal symptoms, does not limit the duration of use,
allows the use in breast cancer survivors if medically advised
Europe
2011 Meta-/reanalytic safety comparison of iCR with placebo, tibolone and HT regarding breast density Sweden
2011 Meta-analysis on liver safety Europe, China
2005 to 2015 More clinical studies on iCR in Europe, America, Asia International
2012 Cochrane Report on black cohosh (Cimicifuga ssp.) for menopausal symptoms Australia
2013 Corrective reply to Cochrane Report, complete meta-analysis of all nine placebo-controlled studies on efficacy International
2013 Systematic review on efficacy (18 studies) and safety (35 studies); conclusive evidence on efficacy if of licensed
product quality
Germany
2014 Supplementary benefit in myoma patients China
2015 Most recent placebo-controlled study; improvement of sleep quality China
2016 Anniversary. 11,073 patients in 28 clinical studies on efficacy since 2000 (10,883 investigated with a medicinal
product of licensed quality, 89% thereof iCR)
Total
iCR isopropanolic CR extract, MRS Menopause Rating Scale, CNS Central nervous system, PET Positron emission tomography, HT Hormone therapy
erhoben worden waren. Hinweise auf eine Leberto-
xizität ergaben sich nicht (international).
Von 2000 bis 2015 wurden insgesamt 28 klinische
Studien aus Europa, Amerika und Asien zur Wirk-
samkeit von CR veröffentlicht. In diesen Studien er-
hielten 11.073 Patientinnen ein CR-Arzneimittel, 93%
davon iCR. Im Jahr 2013 erschien in Korrektur eines
Cochrane Berichts eine vollständige Metaanalyse aller
9 bis dahin veröffentlichten placebokontrollierten Stu-
dien und bestätigte eine zuverlässige Wirksamkeit von
CR-Arzneimitteln (international) gegen WJB.
Eine aktuelle Studienauswertung ergab, dass sich
Myome bei den Frauen verkleinerten, die ihre WJB
mit iCR im Gegensatz zu Tibolon behandelten (2014,
China). Die jüngste placebokontrollierte klinische
Studie zu iCR stammt aus China. Sie zeigte eine
Verbesserung der Schlafqualität.
Zukünftige CR-Forschung dürfte sich den Themen
Wirkungsmechanismen, möglichen Indikationser-
weiterungen (z.B. Rezidivprophylaxe bei Brustkrebs)
oder Zusatznutzen (z.B. Verbesserung der Fraktur-
raten bei Osteoporose oder kognitiven Fähigkeiten)
widmen. Die bisherigen Fakten aus der klinischen
Forschung (KliFo) zu CR bestätigen die Sicherheit und
Wirksamkeit bei WJB, liefern aber auch wertvolle An-
satzpunkte hinsichtlich Zusatznutzen, Wirkmechanis-
men und mehr.
Introduction
The current issue of the Wiener Medizinische Wochen-
schrift is dedicated to therapy with products con-
taining herbal ingredients. Rigorously and rationally
investigated herbal medicinal products are available
for use in humans. Examples thereof are products
containing herbal medicinal preparations (extracts)
made from the rhizome of Cimicifuga racemosa (L.)
Nutt. (CR, synonym for the botanical reclassification
name Actaea racemosa L.), Traubensilberkerze, Black
cohosh). 60 years ago, in 1956, the career of the
first controlled regular medicinal product using this
raw material commenced after centuries of its use in
North American folk medicine. During these 60 years,
extracts made from CR have gained worldwide im-
portance as therapy for menopausal symptoms. In
consideration of this anniversary, the current article
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Table 2 KuppermanMenopause Index (KMI).Original
wording, coding andexample [7, 8]
Symptoms Factor Severity Numerical
Conversion
Vasomotor 4 + = 3 12
Paraesthesia 2 M = 2 4
Insomnia 2 M = 2 4
Nervousness 2 S = 1 2
Melancholia 1 0 = 0 0
Vertigo 1 0 = 0 0
Weakness (fatigue) 1 M = 2 2
Arthralgia and myalgia 1 S = 1 1
Headaches 1 + = 3 3
Palpitation 1 M = 2 2
Formication 1 S = 1 1
Menopausal index 31
Code
0 – none = 0
S – slight = 1
M – moderate = 2
+ – marked = 3
describes the progress of clinical research evidence
on CR during the decades since its official birthdate
(Table 1).
Menopausal symptoms
More than 1.2 billion women in the world will go
through menopause by the year 2030 [1]. For a few
women, this natural process of aging runs its course
asymptomatically, while approximately four out of
five women suffer from MPS; this includes MPS
caused by surgery, chemotherapy or pelvic radiation.
Worldwide, between 50 and 85% of these women
experience severe and disabling symptoms, which
significantly affect their wellbeing and quality of life
[1–3]. MPS comprise hot flushes and (night) sweats,
as well as sleep disturbances associated with these
symptoms. Many women also suffer from psycholo-
gical symptoms such as mood disorders, nervousness
and irritability. The duration of these bothersome
menopausal symptoms is estimated to be about 8
to 12 years [4, 5]. These are important reasons for
seeking medical attention and for receiving therapy.
Product birthdate 1956
The first medicinal product produced from black
cohosh has been available since 1956 (Remifemin®).
Two galenic formulations for oral intake were launched:
tablets containing the isopropanolic extract iCR and
a solution containing an ethanolic extract. Shortly
thereafter, the first publication described clinical ex-
periences in treating climacteric complaints with the
new product [6]. At about the same time, Kupperman
established his Menopause Index (KMI, 1953–1959) [7,
8]. It is calculated as the sum of severity coefficients
Table 3 Observational clinical studiesonCimicifuga race-
mosaduring the first decadeafter launchofRemifemin®.
(A reference list of theseold studies is available from theau-
thor on request)
Author, year of publication No. of patients
Kesselkaul, 1957 62













of the 11 most common symptoms with assigned
symptom-specific weight factors (Table 2). The KMI
has since been used in numerous clinical studies, also
with iCR.
Clinical studies in the 50s to the 70s
From the 50s to the 70s, clinical research on CR fol-
lowed the common practice of documenting and pub-
lishing clinical findings. Practicing gynaecologists and
general practitioners, as well as outpatient depart-
ments of hospitals documented their experiences per
patient on simple case record forms reflecting medical
routine. Thirteen publications with a total of 1810 pa-
tients resulted from these systematic clinical observa-
tions (Table 3). However, their relevance for the to-
tal body of evidence on CR has decreased due to the
availability of new evidence complying with modern
standards for clinical studies.
Changes in the 80s towards controlled studies
Whereas the German Medicines Act from 1961 obliged
manufacturers to notify anymedicinal product to a list
only, the thoroughly revised German Medicines Act
from 1976 enacted the manufacturer’s obligation to
provide proof of quality, safety and efficacy of exist-
ing and new medicinal products. A transition period
was granted for existing drugs until 1990. In the first
years after this new legislation, in-depth discussions
were held to figure out how to prove these three as-
pects. Besides the scientific necessities, this debate
also included emotional aspects such as the accusing
headline on the cover page of the journal Der Spiegel
in 1978, stating “Menschenversuche in deutschen
Krankenhäusern” (Experiments on Humans in Ger-
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Table 4 MenopauseRatingScale (MRS-I). The investigatorassesseseachof ten itemsonascale ranging from0(nocomplaints)
to1(severesymptoms)inincrementsof0.1. Subsequentlytotheoriginalscale[14],subscoreswereestablishedbyfactoranalyses
[15]. Total score andsubscoresare calculatedas themeanof thecomprising items
Item Pertaining to subscore Symptom group Climacteric symptoms
1 HOT FLUSHES Hot flushes, sweating Sensation of rising heat, outbreaks of sweating (frequency/intensity per 24 h)
2 SOMA Cardiac symptoms Palpitations, racing heartbeat, irregular beats, tightness in chest
3 HOT FLUSHES Sleep disorders Difficulty in falling asleep, difficulty in remaining asleep through the night, waking
too early
4 PSYCHE Depressive moods Despondency, sadness, tearfulness, lack of drive, mood fluctuations
5 PSYCHE Nervousness, irritability Nervousness, inner tension, aggressivity
6 PSYCHE Impaired performance/memory Susceptibility to physical and mental exhaustion, poor concentration, forgetfulness
7 ATROPHY Disorders of sexuality Reduced libido, sexual activity and satisfaction
8 ATROPHY Urinary symptoms Symptoms during urination, frequent need to pass urine, accidential incontinence
9 ATROPHY Vaginal dryness Feeling of dryness of the vagina, symptoms during sexual intercourse
10 SOMA Joint and muscle symptoms Pain predominantly affecting the finger joints, rheumatic symptoms, itching
man Hospitals; http://www.spiegel.de/spiegel/print/
d-21112940.html). Scientific societies discussed pos-
sible clinical study designs from methodological per-
spectives, e. g. the German Association of Medical
Documentation, Informatics and Statistics (GMDS),
who dedicated their annual congress to the motto
“Therapy Studies—Planning, Realization, Results, Im-
pact” in 1981. Medical scientists and biometricians
stated to appreciate randomized controlled trials
(RCTs) which appropriately followed in the 1980s
for numerous medicinal products, including head-to-
head-studies of iCR against reference therapies [9, 10].
When answers to the methodological question “how”
seemed to have become settled, first detailed rules
enacted a regulatory framework for clinical trials, i. e.
from 1985 to 1987, the German Ministry of Health
established standards on how to conduct clinical
trials for drugs, i. e. medicinal products [11]. Accord-
ingly, the first double-blind, randomized, placebo-
controlled clinical trial with CR was also conducted
during these years (report 1986, publication 1987,
Germany) [12]. This study investigated iCR for its
efficacy as measured by the KMI in 80 patients. It
revealed a significant superiority of iCR to placebo
for alleviating climacteric complaints in the 12-week
treatment period, with an onset of efficacy before the
first post-baseline visit at 4 weeks [12].
Consequently, the German Commission E ap-
proved a positive benefit–risk balance of Cimicifuga
racemosa for the treatment of climacteric neurovege-
tative complaints [13].
GCP and the MRS enter the stage in the 90s
Good Clinical Practice (GCP) first came into ef-
fect in Europe in 1991 and was harmonized by the
International Conference(s) of Harmonization (ICH)
in 1996 (http://www.ich.org/fileadmin/Public_Web_
Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_
Guideline.pdf). GCP is an international ethical and
scientific quality standard for designing, conducting,
recording and reporting trials that involve the par-
ticipation of human subjects. Compliance with this
standard provides public assurance that the rights,
safety and wellbeing of trial subjects are protected
and are consistent with the principles that have their
origin in the Declaration of Helsinki, and that the
clinical trial data are credible. Although it started
as a guideline, it was subsequently implemented to
mandatory law by GCP directives of the EU council
(2001/20/EC) and the EU commission (2005/28/EC).
In 1994, Hauser published his Menopause Rating
Scale MRS as a new tool to measure menopausal
symptoms [14]. This was a reaction to criticism of the
KMI regarding its weighing of symptoms and the in-
completeness of its profile of menopausal symptoms.
The MRS used a vocabulary of modern language to
describe the symptoms assessed by the ten items of
the score (Table 4). It took another 6 years to make
this new scale ripen. In particular, an additional
advantage arose with the establishment of the four
MRS-I subscores by factor analysis in a large-scale
clinical study in several thousand patients in 2000
([15]; Table 4). Additionally, a self-assessment version
appeared as MRS-II [16] and is meanwhile available
in 27 languages.
The first GCP compliant clinical study with black
cohosh in 1995 investigated iCR in a multicentre set-
ting in Poland and was dedicated to the question of
the dose–efficacy relationship. 152 patients suffering
frommenopausal complaints were randomly assigned
to the treatment groups and assessed using the KMI
and routine safety parameters including laboratory
parameters. Daily doses of iCR extract of up to 127mg
CR proved to be safe and did not influence oestrogenic
parameters such as luteinizing hormone (LH), follicle
stimulating hormone (FSH), serumoestradiol (E2), sex
hormone-binding globulin (SHBG), prolactin or vagi-
nal cytology [17]. Without differentiating according to
menopausal status, iCR extract from 40mg CR already
showed sufficient efficacy in terms of significant im-
provement of the KMI in comparison to baseline [17].
The response rates (KMI < 15) were 72 and 90% after
3 and 6 months of treatment, respectively. However,
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perimenopausal women profited more from iCR ex-
tract from 127 mg CR than from 40mgCR [18].
Several placebo-controlled or reference-con-
trolled studies in the 2000s
The second double-blind randomized placebo-con-
trolled clinical study for iCR followed from 2002 to
2005, in a multicentre setting in Germany. 304 pa-
tients suffering from menopausal complaints parti-
cipated and were assessed using the MRS, its MRS
subscores and routine safety parameters [19]. In
addition proving efficacy again, this study revealed
factors that influence efficacy and found first subtle
hints of a supra-hypothalamic CNS influence of iCR
[19]. Women during their first years of menopausal
complaints showed a better superiority to placebo in
terms of improvement of their symptoms than those
who had been suffering from their complaints for
several years [19]. The effect size was 0.03 to 0.05
MRS units, which is similar to HT study results (0.036
MRS units, see below), thus showing its clinical rel-
evance. Besides superiority in the MRS total score
as the primary efficacy endpoint, the MRS subscore
“HOT FLUSHES” (also named vasomotor symptoms,
VMS) was the most prominent set of symptoms sen-
sitive to improvement by iCR. This “key competence”
of iCR comprises the MRS description “hot flushes,
sweatings and associated sleep disorders” (Table 4).
Adverse events and other safety parameters were
similar in both treatment groups [19].
At approximately the same time, the first placebo-
controlled study with a Cimicifuga product from an
ethanolic extract (Klimadynon®) was performed in the
Czech Republic and published in 2003. Only 62 pa-
tients were evaluable for efficacy after having been
randomly allocated to receive a placebo, the CR ex-
tract or hormone therapy. Unfortunately for the in-
vestigators, their CR effect (0.037 MRS units) narrowly
missed the significance level due to this too small
sample size. However, the particular contribution of
this study is that it strengthens the MRS by estab-
lishing the MRS-based effect size of hormone ther-
apy (HT) for menopausal symptoms, i. e. 0.036 MRS
units compared to placebo [20]. Additionally, CR and
HT led to beneficial effects on serum parameters of
bone metabolism and an increase in vaginal superfi-
cial cells, but, in contrast to HT, there was no CR effect
on endometrial thickness.
Subsequent controlled studies published in 2005
and 2007 that compared iCR (Remifemin®) with other
MPS therapies showed no relevant differences in
efficacy compared to oestradiol patches [21] and ti-
bolone, but iCR was superior regarding safety [22].
In detail, the comparison to oestradiol patches [21]
for a 3-month treatment was performed in 64 pa-
tients in Italy. The efficacy parameters (hot flush
diary, Greene scale) significantly improved over time,
without relevant differences between the treatment
groups. Serum hormone levels (LH, FSH, oestradiol,
prolactin), safety-relevant serum enzymes for liver
function and endometrial thickness did not change
over time in the iCR-group. Interestingly in contrast,
LDL levels (low density lipoprotein) decreased and
HDL levels (high density lipoprotein) increased over
time in the iCR-group [21]. The comparison of iCR
to tibolone [22] was a double-blind, randomized con-
trolled study and the first study on a CR-based herbal
medicinal product with licensed pharmaceutical qua-
lity in an Asian population, particularly in China.
This study was necessary and pivotal for the regula-
tory approval of iCR in that country. As yet, no other
CR extract has been approved by the Chinese regu-
latory authority (SFDA). 244 patients were included
and applied either iCR or tibolone for 3 months. The
well-established Chinese version of the KMI served
as the efficacy parameter and significantly improved
over time, without relevant differences between the
treatment groups, even for moderate to severe symp-
toms. The KMI responder rate was also similar in both
groups (84% and 85%). The safety evaluation showed
a good safety and tolerability profile for both groups;
however, there was a significantly lower incidence of
adverse events (p < 0.0001) in favour of the herbal
treatment. In particular, none of the postmenopausal
iCR patients experienced vaginal bleeding in con-
trast to tibolone (17 cases). As a result, the primary
endpoint (benefit–risk balance), which had been pre-
specified in the study protocol as the combination
of the Mann–Whitney values of the KMI and the fre-
quency of adverse events, also showed superiority of
iCR to tibolone (p = 0.009).
In 2008, another CR product (Remixin®) con-
tributed a controlled study comparing CR to fluoxe-
tine, with inferiority in the psychological component
of the MPS and superiority in the KMI (Turkey) [23].
It’s in the brain: pathophysiology of hot flushes/
sweating and iCR effects seem to match
Pharmaceutical products with proven efficacy, safety
and reproducible pharmaceutical quality are a matter
of interest regarding their mode of action. Hence, iCR
was also investigated for pharmacodynamic effects.
Several preclinical studies argue for an oligo-factorial
mode of action of CR extracts (see below), including
effects on CNS-relevant systems. Clinically, a mile-
stone was reached in 2005 by a poster at the annual
conference of the North American Menopause Soci-
ety and 2008 by the corresponding full publication,
i. e. a clinical study proved a CNS influence of iCR
using positron-emission tomography (USA) [24]. The
authors had treated postmenopausal women with iCR
for 3 months and found changes in µ-opioid receptor
availability in distinct brain regions. In detail, iCR
increased opioid-binding in regions known to be rele-
vant for emotional and cognitive functions (thalamus,
nucleus accumbens, posterior and anterior cingulum)
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and decreased the opioid binding in the dorsoanterior
cingulum and the anterior insular cortex. Although
these regions are known to be oestrogen-sensitive, the
iCR effects were not oestrogenic because iCR alone did
not change the frequency of the LH pulse, whereas iCR
in combination with the opioid antagonist naloxone
did decrease this frequency [24].
Interestingly and consistently, some of these re-
gions were identified during those years as also being
in the pathophysiology of hot flushes and sweating
[25]. In detail, Freedman et al. compared brain acti-
vation in symptomatic postmenopausal women and
asymptomatic eumenorrheic women in their con-
trolled laboratory study using magnetic resonance
imaging. Areas of activation during hot flashes in
symptomatic women included the insula and an-
terior cingulate cortex. Sweating in eumenorrheic
women was associated with activity in the anterior
cingulate and superior frontal gyrus. The authors
concluded that thermoregulation in humans appears
to be represented in a distributed cortico–subcortical
network rather than in a single localized structure
[25].
This matching of Reame’s [24] and Freedman’s data
[25] accords with preclinical results. CR/iCR contains
substances which bind to serotonin, dopamine, GABA
and µ-opioid brain receptors leading to receptor-me-
diated functional activity [26–30]. CR/iCR modulates
the ratio of cerebral monoamines andmetabolites [31]
as well as brain activity (EEG) [32], i. e. serotoner-
gic and dopaminergic systems and µ-opioid receptor
availability [29]. iCR ameliorates an ovariectomy-in-
duced decrease in a serotonin dorsal raphe–preoptic
hypothalamus pathway [33]. iCR recovered the activ-
ity of neurons in the preoptic area in the hypothala-
mus which were impaired by oestrogen deprivation
[34, 35]. After iCR treatment, neurons recovered their
sensitivity to temperature changes and were identi-
fied as active neurons [34]. These data suggest that
alleviation of VMS by CR/iCR is not caused by oestro-
gen-agonistic effects. The hypothesis of an associa-
tion between CNS receptor-mediated effects and an
efficacious relief of VMS has become more plausible,
since iCR binds to CNS receptors andmodulates brain
function and metabolism involved in thermoregula-
tion. Future research is needed to verify this hypoth-
esis.
Upscale of sample size and duration of clinical
studies
The largest clinical study with CR to date (N = 6141 fe-
male patients) was presented at the annual conference
of the German Menopause Association in 2005 and
fully published in 2007. For the first time, it included
over 12 months of safety data on patients (N = 736)
[36]. 1287 gynaecologists [36] in Germany included
women suffering from and treated for their VMS or cli-
macteric mood symptoms or both into this prospec-
tive, controlled, open-label, non-interventional study.
iCR was compared with the combined product con-
taining iCR and St. John’s wort (HP). Patients were
followed up for 6 months, optionally 12 months if
treated for this duration. The primary effectiveness
variable was the MRS subscore “psyche” at month 3
and evaluated by ANCOVA (analysis of covariance).
This MRS subscore comprises climacteric depressive
moods, nervousness, irritability and impaired cogni-
tive functions (Table 4). The total MRS score improved
with both regimens during the first 3 months, further
improved over time during the subsequent 3 months,
and did not change anymore during months 6 to 12.
iCR-HP was superior to iCR in the primary endpoint,
i. e. showed an additional benefit in the psychological
component of MPS, i. e. climacteric mood complaints
[36]. The study did not find any suspicion of liver-
related side effects. The rate of possibly treatment-re-
lated adverse events was 0.16%, all non-serious. The
global assessment of tolerability revealed this to be
good or very good in more than 90% of the patients
[36].
Proof of efficacy for this combination was also
achieved using a double-blind, randomized, placebo-
controlled study (2006) [37]. The study included
301 patients for treatment with the iCR-HP combina-
tion for 4 months in Germany and found a 50% MRS
improvement by this herbal treatment in comparison
to 20% in the placebo group (p < 0.001). The study ad-
ditionally assessed the climacteric mood complaints
using the Hamilton Depression Scale (HAMD) and
revealed a 42% HAMD improvement with the iCR-
HP medication in comparison to 13% in the placebo-
group (p < 0.001). The frequency and pattern of ad-
verse events, safety laboratory results and the clinical
global impression of tolerability were similar in both
treatment groups [37].
Clinical safety at endometrium and breast
In 2006, a clinical study on safety at the endometrium
with a 12-month CR therapy followed. This prospec-
tive, open-label, multicentre study in Poland and the
Czech Republic included 400 patients, assessed them
by ultrasonography and did not find any case of en-
dometrial hyperplasia or any increase of the mean of
the endometrial thickness over time [38].
The safety of iCR on breast tissue was also substan-
tiated with a clinical study: in 2007 alone (N = 64) [39]
and in 2011 in a meta-analysis together with a pre-
ceding study comparing placebo (N = 53), HT (N =
43) and tibolone (N = 49) [40]. Both studies were per-
formed in the same setting at the Karolinska Hospital
in Stockholm, Sweden. Blinded observers compared
the baseline status of mammography (breast density)
and fine-needle aspiration biopsy (breast cell prolifer-
ation assessed as the frequency of Ki-67-positive cells)
with the status after 6 months of treatment. Breast
density remained unchanged in the placebo group
60 years of Cimicifuga racemosa medicinal products K
main topic
and the iCR group (0% and no case more than 5%)
but significantly increased (p < 0.001) in the HT group
(+14.3% and 27 cases more than 5%) and the tibolone
group (+2.3% and 10 cases more than 5%) [40]. Fur-
thermore, there was no increase in breast cell prolif-
eration upon iCR treatment, i. e. no increase in the
mean/median proportion of Ki-67-positive cells [39].
The mean/median change in ultrasonographically in-
vestigated endometrial thickness was 0 [39]. These
clinical study data on iCR do not give any indication
of adverse effects on healthy breast tissue or any en-
dometrial safety concerns [39].
In 2007, a pharmacoepidemiological cohort study
demonstrated a 4.5 year longer recurrence-free sur-
vival after breast cancer for iCR users [41]. This study
examined the data of breast cancer patients treated at
general, gynaecological and internal facilities linked
to a medical database in Germany. The impact of
treatment with iCR following diagnosis was analysed
by Cox proportional hazards models, controlling for
age and other confounders. Of 18,861 patients, a to-
tal of 1102 had received an iCR therapy (either iCR
alone or the iCR-HP combination). The mean over-
all observation time was 3.6 years. iCR exposure was
not associated with an increase in the risk of recur-
rence but was associated with prolonged disease-free
survival. 2 years after initial diagnosis, 14% of the con-
trol group had developed a recurrence, while the iCR
group reached this proportion after 6.5 years. The pri-
mary Cox regressionmodel controlling for age, tamox-
ifen use and other confounders demonstrated a pro-
tractive effect of iCR on the rate of recurrence (hazard
ratio 0.83, p = 0.039). This effect remained consis-
tent throughout all variations of the statistical model,
including subgroup analyses. TNM status was un-
known but did not bias the iCR treatment decision
(due to climacteric complaints) as investigated sep-
arately. Once in a while, this study is criticized for
this TNM uncertainty in the dataset. However, due to
the independency of the treatment decision from the
TNM status, the missing of TNM information is not
a source of bias for the comparison of iCR-users with
nonusers regarding the endpoint of this study. No-
tably, the missing TNM data even impaired the power
of the study to detect any group difference on a sig-
nificant level because its impact cannot be deducted
from the overall variance of the endpoint. But if a de-
tected difference is already significant, such impair-
ment of power becomes irrelevant. In contrast, if end-
point and reason for treatment allocation depend on
the same confounder, this can cause bias and should
not suffer from missing data and should be included
into the regression model (cofactor/covariate or stra-
tification). This applies for the confounders age and
tamoxifen use, and the study’s analyses appropriately
cared for this [41]. In particular, the beneficial recur-
rence protractive effect of iCR occurred in tamoxifen-
users and also in tamoxifen-nonusers [41].
HMPC monograph and meta-analyses
In 2010, the HMPC attested the well-established use
of medicinal products containing CR extract based
on previously published studies on menopausal
symptoms [42]. An essential precondition of reg-
ulatory authorities’ approval of products based on
such monographs is the proof and approval of its
product-specific pharmaceutical quality. The phar-
maceutical characteristics of HMPC-accepted herbal
medicinal products made from Cimicifuga racemosa
comprise the “quantitative and qualitative composi-
tion” requiring “dry extract (drug–extract ratio, DER
5-10:1), extraction solvent ethanol 58%” or “dry ex-
tract (DER 4.5-8.5:1), extraction solvent ethanol 60%”
or “dry extract (DER 6-11:1), drug extraction solvent
isopropanol 40%”. Notably, the HMPC monograph
does not limit the length of the use of CR extracts,
but after 6 months of therapy, a medical professional
should be consulted. The reason behind this is that
women who usually suffer from MPS are in a certain
age range when they should see their doctor any-
way, in order to avoid overseeing any serious disease.
Also, breast cancer patients are not excluded from
the treatment of MPS with CR as long as a medical
professional is consulted. This is actually a matter of
course, because physicians who treat cancer patients
should know every medicinal product their patients
take [42].
The clinical data on the safety of CR extracts in en-
dometrium, liver, breast and breast cancer were fur-
ther augmented by numerous supportive preclinical
studies in animals and cell cultures. For preclinical
details, refer to the assessment report of the HMPC
monograph on CR [42].
In 2011 the first meta-analysis was dedicated to the
topic of liver safety [43]. In all five controlled clinical
studies with iCR available from any country at that
time, the liver function test values were summarized
where they had been raised. The dataset comprised
1117 peri- or postmenopausal women who treated
their symptoms with iCR for 3 to 6 months. The
dosages of the extracts corresponded to 40–128mg
herbal substance per day. The meta-analysis did not
find any group difference regarding the safety-relevant
serum enzymes for liver function, particularly also
neither at the highest dosage nor upon the longest
duration of exposure. Evidence of liver toxicity was
not found [43]. This accords with the safety results
of a recent systematic review [44] and its update [45],
which did not find any case of hepatotoxicity among
the more than 12,000 patients in all clinical studies on
the safety of CR-based study medication.
This systematic review [44] and its update [45] cer-
tified an Oxford level of evidence 1a (safety) or 1b (ef-
ficacy) and grade of recommendation A for the iCR,
with lower level of evidence and grade of recommen-
dation for other CR extracts. Particularly the efficacy
aspect of this systematic review deserves further at-
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Table 5 Placebo-controlled studiesonCimicifuga racemosa for alleviating naturalmenopausal complaints. For bibliographic
details of these studies seeBeer et al. [47]
Author, year Licensed medicinal
product
Number of patients Standardized difference in
means
95% confidence interval
Frei Kleiner 2005 Yes 122 –0.090 –0.461 to 0.281
Geller 2009 No 43 0.170 –0.408 to 0.748
Amsterdam 2009 No 28 0.430 –0.286 to 1.146
Newton 2006 No 164 –0.270 –0.578 to 0.038
Osmers 2005 Yes 286 –0.394 –0.626 to –0.162
Stoll 1987 Yes 50 –1.020 –1.586 to –0.454
Wuttke 2003 Yes 40 –0.639 –1.260 to –0.018
Kaiser 2008 Yes 120 –0.617 –0.975 to –0.259
Li Yilin Yes 77 –0.792 –1.246 to –0.338
Meta-analysis summary of
efficacy
Any 930 –0.385 –0.514 to –0.255
(p < 0.0001)
tention, because the reviewer figured out a very im-
portant key point for interpretation of efficacy results
of all recent studies: conclusive evidence on efficacy
if of licensed-product quality, inconclusiveness only
if other quality was investigated. From 2000 to 2015,
a total of 29 clinical studies in Europe, America and
Asia were published on the efficacy of CR. In these
studies 10,049 patients received a CR-based medici-
nal product, 93% thereof iCR (Fig. 1; [44–46]).
In 2013 a corrective reply to the Cochrane Report
on black cohosh—Cimicifuga ssp. in 2012 presented
a complete meta-analysis of all nine placebo-con-
trolled studies published till then; the report con-
firmed the reliable efficacy of CR-based medicinal
products. The result of this meta-analysis estimates
the standardized effect size in comparison to placebo
to be 0.385 standard deviations (p < 0.0001; Table 5;
[47]).
Supplemental benefits and upfront potential
A recent study analysis evidenced that in women who
were treated with iCR for MPS, the myomas shrank
in size compared to therapy with tibolone (2014) [48].
The dataset of this supplemental analysis was a sub-
set of the randomized controlled study comparing iCR
and tibolone in menopausal complaints in China [22]
and comprised all 62 patients with at least one uter-
ine fibroid at onset of treatment. The size of the fi-
broids had been measured by transvaginal ultrasono-
graphy. The median myoma volume decreased with
iCR for 3 months by as much as –30% (p = 0.016),
but increased with tibolone by +4.7%. The latter cor-
responds to the +4.4% that can be expected for un-
treated myoma patients of similar age.
Data from four clinical trials [49–52] hint at be-
neficial effects of CR on bone metabolism and bone
mineral density which might help to reduce the cu-
mulative dose of HT for prophylaxis of osteoporosis.
The latest placebo-controlled clinical study with
iCR came from China. It showed the improvement of
sleep quality in postmenopausal women with sleep
disturbances [53].
Adverse drug reactions
The profile of adverse drug reactions (ADR) which
emerged from all the clinical studies and from phar-
macovigilance monitoring is summarized in the pack-
age insert leaflet and in the summary of product cha-
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racteristics of licensed medicinal products accord-
ing to the HMPC monograph and comprises for iCR:
Rarely: gastrointestinal symptoms, allergic skin reac-
tions, facial or peripheral oedema, increase of liver
enzymes in the serum, increase of body weight. Very
rarely, cases of liver toxicity were reported during
the use of Cimicifuga products. However, a causal
relationship has not yet been confirmed.
To date, none of all the clinical studies on the safety
of CR-based studymedication found any case of hepa-
totoxicity among their more than 12,000 participating
patients.
Long-term treatment
The duration of use of medicinal products intended
for non-life-threatening diseases is directly linked to
a positive risk–benefit assessment based on clinical
data over distinct exposure periods according to the
ICH-E1 guideline (http://www.ema.europa.eu/docs/
en_GB/document_library/Scientific_guideline/2009/
09/WC500002747.pdf). For a long-term treatment,
this guideline requires that the number of patients
monitored for ADR in clinical studies:
● should be at least 300–600 treated for 6months. This
principle is fulfilled already by the 6141 patients ex-
posed to iCR for at least 6 months in the study by
Briese et al. [36] and several additional hundreds of
patients in all the other clinical studies on iCR (for
a complete list see [44] and its update [45]).
● should be at least 100 treated for 12 months. This
principle is fulfilled by the 736 patients exposed to
iCR for 12months in the study by Briese et al. [36].
● should be at least 1500 treated for any duration. This
principle is fulfilled by the total number of about
12,000 patients exposed to iCR in interventional and
non-interventional clinical studies [36, 44, 45].
One may discuss whether the chapter “exceptions” in
ICH-E1 applies, e. g. if concerns had arisen from an-
imal studies. However, the chronic toxicity studies
available for the iCR products did not reveal such con-
cern (unpublished preclinical study reports available
at the regulatory authorities who granted marketing
authorizations of these products).
Sufficient clinical study data are available, at least
for iCR among the CR extracts, to fulfil the ICH-E1 set
of principles for a safe long-term treatment (chronic
or repeated intermitted use longer than 6 months).
Independently from the sufficient extent of preclin-
ical and clinical data supporting the safe use of black
cohosh, all menopausal women should seek routine
medical advice every 6 to 12 months, to avoid other
relevant diseases being overlooked.
Future
Future CR research may be dedicated to such topics
as: mechanisms of action, possible extension of indi-
cations (e. g. prophylaxis for breast cancer recurrence)
or additional uses (e. g. improvement of osteoporosis
fractures or cognitive abilities). To date, the results of
clinical research with CR confirm its safety and effi-
cacy for menopausal symptoms and also provide valu-
able insights into additional uses, the mechanism of
action and more.
Conclusion
The 60 years since the launch of the first CR-based
medicinal product have included preclinical and clin-
ical research (89% of patients investigated used iCR)
showing:
● Efficacy for menopausal complaints, if licensed
medicinal product quality.
● Beneficial and usable already in symptomatic pre-
menopausal patients.
● Possible supplemental benefits (increase of disease-
free survival after breast cancer, adjuvant prophy-
laxis of osteoporosis, shrinkage of myoma, other ef-
fects).
● Safety (iCR fulfils the regulatory requirements on
long-term treatment, is safe at oestrogen-sensitive
tissues such as breast, uterus or tumours, did not
impair tamoxifen or aromatase inhibitors, did not
show hepatotoxicity in clinical studies).
● Differential effects in the periphery and influence
on CNS regions responsible for thermoregulation,
mood and sleep.
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